Excess CCL3 in the setting of myelogenous leukemias and multiple myeloma has been shown to inhibit osteoblastic activity and activate osteoclastic bone resorption leading to overall loss of bone6,7,24. This evidence concerns the gene CCL3 and plasma cell myeloma.